<DOC>
	<DOC>NCT02695771</DOC>
	<brief_summary>To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.</brief_summary>
	<brief_title>The Bladder Instillation Comparison Study</brief_title>
	<detailed_description>This study will compare standard of care treatment for patients with non-muscle invasive bladder cancer (NMIBC). Patients will be randomized to one of three arms, Mitomycin C, Gemcitabine or no additional treatment immediately following TURBT in the operating suite. All treatment, surgical procedures and follow up care will be conducted according to standard of care treatment.</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>1. sign an informed consent for the study 2. be scheduled for a TURBT for suspected nonmuscle invasive bladder tumor. 1. patients unable to consent for themselves 2. individuals under 18 years old 3. pregnant women 4. prisoners 5. patients with known allergy or intolerance to the mitomycin C or Gemcitabine 6. any other sound medical, psychiatric and/or social reason as determined by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>bladder tumors</keyword>
	<keyword>urinary tumors</keyword>
	<keyword>non-muscle invasive bladder tumors</keyword>
	<keyword>NMIBC</keyword>
</DOC>